Last reviewed · How we verify

Nifedipine GITS — Competitive Intelligence Brief

Nifedipine GITS (Nifedipine GITS) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcium channel blocker (dihydropyridine). Area: Cardiovascular.

marketed Calcium channel blocker (dihydropyridine) L-type voltage-gated calcium channel Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Nifedipine GITS (Nifedipine GITS) — Peking University First Hospital. Nifedipine GITS is a long-acting calcium channel blocker that reduces calcium influx into vascular smooth muscle cells, causing vasodilation and lowering blood pressure.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Nifedipine GITS TARGET Nifedipine GITS Peking University First Hospital marketed Calcium channel blocker (dihydropyridine) L-type voltage-gated calcium channel
Amlodipine/Atorvastatin Amlodipine/Atorvastatin Pfizer's Upjohn has merged with Mylan to form Viatris Inc. marketed Calcium channel blocker / HMG-CoA reductase inhibitor (statin) combination L-type voltage-gated calcium channels / HMG-CoA reductase
Lercanidipine/enalapril fixed combination Lercanidipine/enalapril fixed combination Meir Medical Center marketed Calcium channel blocker / ACE inhibitor combination L-type voltage-gated calcium channels; Angiotensin-converting enzyme (ACE)
Amlodipine placebos Amlodipine placebos Shenzhen Ausa Pharmed Co.,Ltd marketed Calcium channel blocker (dihydropyridine) L-type voltage-gated calcium channel
amlodipine/hydrochlorothiazide amlodipine/hydrochlorothiazide Shanghai Jiao Tong University School of Medicine marketed Calcium channel blocker / Thiazide diuretic combination L-type voltage-gated calcium channel (amlodipine); Sodium-chloride cotransporter (hydrochlorothiazide)
Amlodipine (Norvasc) Amlodipine (Norvasc) Bayer marketed Calcium channel blocker (dihydropyridine) L-type voltage-gated calcium channel
Amlodipine+intensive antihypertensive therapy Amlodipine+intensive antihypertensive therapy Beijing Tiantan Hospital marketed Calcium channel blocker (dihydropyridine) L-type voltage-gated calcium channel

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Calcium channel blocker (dihydropyridine) class)

  1. Bayer · 2 drugs in this class
  2. Beijing Tiantan Hospital · 2 drugs in this class
  3. GlaxoSmithKline · 1 drug in this class
  4. Guangzhou First People's Hospital · 1 drug in this class
  5. Organon and Co · 1 drug in this class
  6. Peking University First Hospital · 1 drug in this class
  7. Pfizer Inc. · 1 drug in this class
  8. SK Chemicals Co., Ltd. · 1 drug in this class
  9. Shanghai Jiao Tong University School of Medicine · 1 drug in this class
  10. Shanghai Shyndec Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Nifedipine GITS — Competitive Intelligence Brief. https://druglandscape.com/ci/nifedipine-gits. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: